Royalty Pharma Announces $761 Million Acquisition of Interest in BG-12 and Fumaderm

New York, NY – May 2, 2012 - Royalty Pharma announced today that it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash. The Fumapharm earn-out primarily represents an indirect interest in Biogen Idec’s BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of relapsing-remitting multiple sclerosis (RRMS).

© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.